Related references
Note: Only part of the references are listed.Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Sven Francque et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo
Pierre Ambrosi et al.
CARDIOLOGY (2020)
Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?
Nadine Gehrke et al.
GASTROENTEROLOGY (2020)
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease
Fabio Nascimbeni et al.
JOURNAL OF HEPATOLOGY (2020)
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Sander Lefere et al.
JOURNAL OF HEPATOLOGY (2020)
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study
Francque M. Sven et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2019)
The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH
Rohit Loomba et al.
HEPATOLOGY (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH
Irene Pierantonelli et al.
TRANSPLANTATION (2019)
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
David E. Kleiner et al.
JAMA NETWORK OPEN (2019)
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli et al.
JHEP REPORTS (2019)
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Zobair Younossi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
Determinants of fibrosis progression and regression in NASH
Detlef Schuppan et al.
JOURNAL OF HEPATOLOGY (2018)
Pharmacotherapy for NASH: Current and emerging
Monica A. Konerman et al.
JOURNAL OF HEPATOLOGY (2018)
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
Benaissa Boubia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
The New-Generation Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Protects the Liver From Metabolic Disorders and Fibrosis
Guillaume Wettstein et al.
HEPATOLOGY COMMUNICATIONS (2017)
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
Sven M. Francque et al.
JOURNAL OF HEPATOLOGY (2016)
Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease
Pierre Bedossa
HEPATOLOGY (2014)
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Hannele Yki-Jarvinen
LANCET DIABETES & ENDOCRINOLOGY (2014)
Pioglitazone in the treatment of NASH: the role of adiponectin
A. Gastaldelli et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis
Amalia Gastaldelli et al.
HEPATOLOGY (2009)
NASH and cryptogenic cirrhosis: A histological analysis
Stephen H. Caldwell et al.
ANNALS OF HEPATOLOGY (2009)
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
Bogdan Balas et al.
JOURNAL OF HEPATOLOGY (2007)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Considerations for management of fluid dynamic issues associated with thiazolidinediones
NK Hollenberg
AMERICAN JOURNAL OF MEDICINE (2003)
Share Paper
